Advertisement
Mr. Weidong Yin, Chairman, President and CEO of Sinovac, remarked, "We areexcited to participate in the CPhI Exhibition in Shanghai, where we willfeature our high quality products, such as vaccines against hepatitis A andseasonal influenza. As the exhibition attracts a global audience, we lookforward to meeting with current and potential new international distributionpartners to explore opportunities to further advance our global distributionstrategy."
Advertisement
The Shanghai CPhI Exhibition provides Sinovac and otherexhibitors/attendees with the opportunity to gain a better understanding ofthe global pharmaceutical industry. In 2009, a total of 1,651 exhibitorsattended the event, including 127 overseas companies from 16 countries andregions. In addition to the exhibition booths, CPhI also hosted 54 high levelconferences and seminars during the event, providing exhibitors and attendeeswith the opportunity to further communicate and exchange the latestinformation in the pharmaceutical industry.
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company thatfocuses on the research, development, manufacture and commercialization ofvaccines that protect against human infectious diseases. Sinovac's vaccineproducts include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A andB), and Anflu(R) (influenza). Panflu(TM), Sinovac's pandemic influenza vaccine(H5N1), has already been approved for government stockpiling. Sinovac isdeveloping vaccines for enterovirus 71, universal pandemic influenza, Japaneseencephalitis, and human rabies. Its wholly owned subsidiary, Tangshan Yian, isconducting field trials for independently developed inactivated animal rabiesvaccines. Its 30%-owned joint venture, Sinovac Dalian, focuses on the research,development, manufacturing and commercialization of vaccines, such as rabies,chickenpox, mumps and rubella vaccines for human use.
About CPhI Worldwide
CPhI Worldwide was launched in 1990 as an international convention onpharmaceutical ingredients and intermediates. This inaugural CPhI attracted250 visitors for the 16 exhibitors. Today this has grown to an unrivalled24,000 industry professionals visiting some 1,500 exhibiting companies fromover 125 countries. CPhI is the leading exhibition on pharmaceuticalingredients and allied industries. Each year the exhibition grows larger withexhibitors and visitors conducting significant levels of business at CPhI. Twosister events, ICSE and P-MEC now run alongside CPhI, a tripartite of eventsthat is considered the must attend event for any individual or organisationwithin the pharmaceutical manufacturing community. In 2001 CPhI was launchedin China. ICSE China was launched in 2005 and P-MEC China in 2006.For more information, please contact: Chris Lee Sinovac Biotech Ltd. Tel: +86-10-8279-9659 Fax: +86-10-6296-6910 Email: [email protected] Investors: Amy Glynn/Stephanie Carrington The Ruth Group Tel: +1-646-536-7023/7017 Email: [email protected] [email protected] Media: Jason Rando The Ruth Group Tel: +1-646-536-7025 Email: [email protected]
SOURCE Sinovac Biotech Ltd.
